# US 2017/0239033 A1 · 3d filter for prevention of stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0239033 A1
- Document ID: US20170239033A1
- Status: Published application
- Kind: A1
- Application number: 15/505,451
- Filed: 2015-08-21
- Published: 2017-08-24
- Earliest claimed: 2014-08-21
- Assignees: Frid Mind Technologies
- Applicants: Frid Mind Technologies
- Inventors: Noureddine FRID
- Web page: https://patentgrep.com/patent/US20170239033A1

## CPC

- A61F 2/01: Filters implantable into blood vessels
- A61F 2/90: characterised by a net-like or mesh-like structure
- A61L 31/022: {Metals or alloys}
- A61L 31/08: Materials for coatings
- A61L 31/088: {Other specific inorganic materials not covered by A61L31/084 or A61L31/086}
- A61L 31/14: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61F 2002/016: {made from wire-like elements}
- A61F 2210/0076: multilayered, e.g. laminated structures
- A61F 2230/0006: circular
- A61F 2230/0069: cylindrical
- A61F 2230/008: paraboloidal
- A61L 2400/18: Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present invention relates to implantable endoluminal prosthesis for preventing stroke. The endoluminal prosthesis (1) consists of a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane. Said braided framework (20) is self-expandable comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material. Each layer forms a mesh. The meshes form a lattice with a plurality of wires (2) of given layers (22, 23, 24). The lattice defines polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1). The diameter (Ø25) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (Ø27) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state. The braided framework (20) consists of at least 128 and at most 512 wires (25). The ratio (T1/Ø25) of the thickness (T1) of a wall of said implantable endoluminal prosthesis (1) to the diameter (Ø25) of wire (25) is at least 3.0. In a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%.

## Claims

### Claim 1

An implantable endoluminal prosthesis (1) comprising: a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane, said braided framework (20) being self-expandable, comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material, each layer forming a mesh, the meshes forming a lattice with a plurality of wires (2) of given layers (22, 23, 24), the lattice defining polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1), the diameter (φ25) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (φ27) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state, characterized in that:
the braided framework (20) consists of at least 128 and at most 512 wires (25);
the ratio (T1/φ25) of the thickness (T1) of a wall of said implantable endoluminal prosthesis (1) to the diameter (φ25) of wire (25) is at least 3.0;
in a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%;
when the implantable endoluminal prosthesis (1) is deployed in a curved lumen having a H/W ratio between 0.5 and 0.9, the mean diameter (φ27) of inscribed circle of opening units is at least 75 μm and at most 200 μm, the length-related compression ratio (LCR) being between 15% and 40%, and the surface coverage ratio (SCR) of the braided framework (20) being more than 50% at the side of outer curve.

### Claim 2 (depends on 1)

The implantable endoluminal prosthesis according to claim 1, wherein the meshes are interlocked forming a lattice with a plurality of wires of given layers, the wires being integrated in the mesh of at least one of the adjacent layers such that meshes of adjacent layers of the framework are substantially offset.

### Claim 3 (depends on 2)

The implantable endoluminal prosthesis according to claim 2, wherein the ratio (T1/φ25) is at least 3.5.

### Claim 4 (depends on 3)

The implantable endoluminal prosthesis according to claim 3, wherein the braided framework (20) is at least 256 wires.

### Claim 5 (depends on 4)

The implantable endoluminal prosthesis according to claim 4, wherein the wires are made of biocompatible metal, the surface of said wires being covered with a gem-bisphosphonate, said gem-bisphosphonate groups having the general formula (I),
R3 representing: (i) —C1-16 alkyl unsubstituted or substituted with —COOH, —OH, —NH2, pyridyl, pyrrolidyl or NR5R6; (ii) —NHR7; (iii) —SR8; or (iv) —Cl;
R4 representing —H, —OH, or —Cl;
R5 representing —H or —C1-5 alkyl;
R6 representing —C1-5 alkyl;
R7 representing —C1-10 alkyl or —C3-10 cycloalkyl;
R8 representing phenyl;
at least one of M1, M2, M3 and M4 representing any metallic atom of the external surface of the wire (25), so that at least one phosphonate moiety is covalently and directly bonded to the external surface of the wire (25), and the bisphosphonate covering at least 50% of the external surface of the wires (25) as monolayer and as an outermost layer.

### Claim 6 (depends on 5)

The implantable endoluminal prosthesis according to claim 5, wherein said gem-bisphosphonate is etidronic acid, alendronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid or a derivative thereof.

### Claim 7 (depends on 4)

The implantable endoluminal prosthesis according to claim 4, wherein said wires are coated with phosphonate containing a hydrocarbon chain comprising 3 to 16 carbon atoms as a linear chain, the phosphorus atom of the phosphonate bonding to the hydrocarbon chain at the alpha-position, said hydrocarbon chain being further functionalized at its terminal position by a carboxylic group, a phosphonic group or a hydroxyl group, and at least one of M1 and M2 representing any metallic atom of the external surface of the implantable medical device, the phosphonate being covalently and directly bonded to the external surface of the wire (25) and covering at least 50% of the external surface of the implantable medical device as monolayer and as an outermost layer.

### Claim 8 (depends on 1)

The implantable endoluminal prosthesis according to claim 1, wherein the surface coverage ratio (SCR) of said braided framework (20) is at least 55 in a fully expanded state.

### Claim 9 (depends on 1)

The implantable endoluminal prosthesis according to claim 1, wherein when the implantable medical device (1) is deployed in a curved lumen having H/W ratio between 0.5 and 0.9, the mean diameter (φ27) of inscribed circle of opening units (27) is at least 100 μm and at most 150 μm, the length-related compression ratio (LCR) being between 30% and 40% at the outer side of the curve.

### Claim 10 (depends on 9)

The implantable endoluminal prosthesis according to claim 9, wherein the surface coverage ratio (SCR) of the braided framework (20) is at least 55 at the outer side of the curve.

### Claim 11 (depends on 1)

The implantable endoluminal prosthesis according to claim 1, wherein the diameter (φ25) of the wires (25) is at least 50 μm.

### Claim 12 (depends on 1)

The implantable endoluminal prosthesis according to claim 1, wherein the mean diameter (φ27) of the inscribed circle (27) of the polygonal opening units (26) is at least 100 μm and at most 150 μm in fully expanded state.

### Claim 13 (depends on 4)

The implantable endoluminal prosthesis according to claim 4, wherein the biocompatible material is a metallic substrate selected from the group consisting of titanium, nickel-titanium alloys, any type of stainless steels, or a cobalt-chromium-nickel alloys.

### Claim 14 (depends on 1)

A method for prevention of embolic stroke for patients suffering from atrial fibrillation, rheumatic heart disease, ischemic cardiomyopathy, congestive heart failure, myocardial infarction, post-operatory state or protruding aortic arch atheroma, or having prosthetic valves comprising placing said implantable endoluminal prosthesis of claim 1 in front of aortic arteries which carry blood to the brain.

### Claim 15 (depends on 1)

A method for improving perfusion of an organ comprising: placing said implantable endoluminal prosthesis of claim 1 in the aorta while covering the inlets of arteries which carry blood to the organ.